Covalent inhibitors have received significant research and commercial interest in the last ten years. The ability to irreversibly inhibit an enzyme or to reversibly inhibit it for a prolonged period has allowed biologists to understand the function of proteins and has more recently allowed medicinal chemists and doctors to treat diseases previously recalcitrant to treatment. Using the CAS Content Collection, we investigated research about covalent inhibitor drugs, including journal and patent publication frequencies, the types of warheads used, their biological targets, and the diseases they are intended to treat. The interest in covalent inhibitors has increased significantly, with both journal and patent publications per year increasing linearly over time. Larger US academic institutions such as the University of California system are significant contributors to journal publication, while pharmaceutical companies such as Pfizer publish the largest numbers of patents each year. Academic research tendencies in covalent inhibitors may arise from the origins of covalent inhibitor research [for example, the initial development of covalent K-RAS inhibitors from the Shokat group 309 and thus the institutional experience and their subsequent success. Commercial research may be driven by the increased understanding of the chemical and biological behavior of covalent inhibitor; the need for comprehensive understanding of the behavior of covalent inhibitors by both developers and regulators may require significant technical knowledge and infrastructure to obtain.